NYSE:MEDMedifast Stock Price, Forecast & News

Medifast's stock was trading at $70.44 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MED shares have decreased by 2.3% and is now trading at $68.80. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medifast in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Medifast.

Medifast is scheduled to release its next quarterly earnings announcement on Wednesday, May 6th 2020. View our earnings forecast for Medifast.

Medifast Inc (NYSE:MED) released its quarterly earnings data on Wednesday, February, 26th. The specialty retailer reported $1.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.07 by $0.59. The specialty retailer had revenue of $170.63 million for the quarter, compared to analysts' expectations of $162 million. Medifast had a return on equity of 62.24% and a net margin of 10.92%. View Medifast's earnings history.

Medifast declared a quarterly dividend on Thursday, March 19th. Shareholders of record on Tuesday, March 31st will be given a dividend of $1.13 per share on Wednesday, May 6th. This represents a $4.52 dividend on an annualized basis and a dividend yield of 6.57%. The ex-dividend date is Monday, March 30th. View Medifast's dividend history.

Medifast updated its FY20 earnings guidance on Wednesday, February, 26th. The company provided earnings per share guidance of $6.25 to $6.55 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.84. The company issued revenue guidance of $715.0 million to $745.0 million, compared to the consensus revenue estimate of $798.90 million.

3 analysts have issued 1 year price targets for Medifast's shares. Their forecasts range from $83.00 to $90.00. On average, they expect Medifast's stock price to reach $86.50 in the next twelve months. This suggests a possible upside of 25.7% from the stock's current price. View analysts' price targets for Medifast.

News coverage about MED stock has trended very negative recently, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Medifast earned a news sentiment score of -3.3 on InfoTrie's scale. They also gave news stories about the specialty retailer a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutMedifast.

Medifast saw a drop in short interest during the month of March. As of March 13th, there was short interest totaling 3,583,600 shares, a drop of 5.7% from the February 27th total of 3,800,000 shares. Based on an average daily trading volume, of 299,100 shares, the short-interest ratio is presently 12.0 days. Approximately 31.9% of the shares of the stock are sold short. View Medifast's Current Options Chain.

Some companies that are related to Medifast include Estee Lauder Companies (EL), Herbalife Nutrition (HLF), Avon Products (AVP), Prestige Consumer Healthcare (PBH), USANA Health Sciences (USNA), Inter Parfums (IPAR), Nu Skin Enterprises (NUS), Revlon (REV), Veru (VERU) and Nature's Sunshine Products (NATR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Medifast investors own include NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Home Depot (HD), Mastercard (MA), Paypal (PYPL), AbbVie (ABBV), Baidu (BIDU), Boeing (BA) and Adobe (ADBE).

Medifast trades on the New York Stock Exchange (NYSE) under the ticker symbol "MED."

Medifast's stock is owned by a number of retail and institutional investors. Top institutional investors include Chickasaw Capital Management LLC (0.28%), State of Alaska Department of Revenue (0.09%) and FNY Investment Advisers LLC (0.02%). Company insiders that own Medifast stock include Carl E Sassano, Constance J Hallquist, Daniel R Chard, Michael A Hoer and Scott Schlackman. View institutional ownership trends for Medifast.

MED stock was sold by a variety of institutional investors in the last quarter, including Chickasaw Capital Management LLC. View insider buying and selling activity for Medifast.

MED stock was acquired by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC, and State of Alaska Department of Revenue. Company insiders that have bought Medifast stock in the last two years include Daniel R Chard, and Michael A Hoer. View insider buying and selling activity for Medifast.

Shares of MED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MED stock can currently be purchased for approximately $68.80.

Medifast has a market capitalization of $809.43 million and generates $713.67 million in revenue each year. The specialty retailer earns $77.92 million in net income (profit) each year or $5.96 on an earnings per share basis. Medifast employs 420 workers across the globe. View additional information about Medifast.

The official website for Medifast is http://www.medifast1.com/.

Medifast's mailing address is 100 International Drive, Baltimore MD, 21202. The specialty retailer can be reached via phone at 410-581-8042 or via email at [email protected]